Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biontech Se ADR
(NQ:
BNTX
)
96.95
-2.05 (-2.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biontech Se ADR
< Previous
1
2
3
4
5
6
7
8
9
...
61
62
Next >
ROSEN, A RANKED AND LEADING FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 23, 2024
WHY: NEW YORK, NY - (NewMediaWire) - January 23, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Enphase Energy To Rally Over 35%? Here Are 10 Top Analyst Forecasts For Tuesday
January 23, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Key Takeaways From BioNTech Analyst Ratings
January 23, 2024
Via
Benzinga
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 22, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
P/E Ratio Insights for BioNTech
January 09, 2024
Via
Benzinga
Comparative Study: BioNTech And Industry Competitors In Biotechnology Industry
January 03, 2024
Via
Benzinga
How Is The Market Feeling About BioNTech?
December 26, 2023
Via
Benzinga
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
January 22, 2024
From
BioNTech SE
Via
GlobeNewswire
BIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE
January 22, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
January 22, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 21, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
BNTX ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against BioNTech SE (BNTX)
January 20, 2024
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 20, 2024
WHY: NEW YORK, NY - (NewMediaWire) - January 20, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
The Law Offices of Frank R. Cruz Announces Investigation of BioNTech SE (BNTX) on Behalf of Investors
January 19, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 19, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
January 18, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
BioNTech SE (BNTX) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Filed Against BioNTech SE
January 18, 2024
From
Robbins LLP
Via
Business Wire
BIONTECH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm
January 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
BIONTECH SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options
January 17, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
January 17, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here.
Via
Benzinga
BIONTECH SE SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioNTech SE (NASDAQ: BNTX)
January 16, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BNTX
January 16, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
January 15, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
BioNTech Prepares To Be Commercial Ready By 2025, Revenue Growth Expected To Return In 2025
January 09, 2024
On Tuesday, BioNTech SE (NASDAQ: BNTX) outlined priorities at the Annual J.P.
Via
Benzinga
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
January 09, 2024
From
BioNTech SE
Via
GlobeNewswire
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
January 07, 2024
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...
Via
Talk Markets
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
5 Value Stocks To Watch In The Healthcare Sector
January 01, 2024
Via
Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
61
62
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.